Novo Nordisk Statistics

Total Valuation

Novo Nordisk has a market cap or net worth of EUR 262.63 billion. The enterprise value is 272.97 billion.

Market Cap	262.63B
Enterprise Value	272.97B

Important Dates

The last earnings date was Wednesday, May 7, 2025.

Earnings Date	May 7, 2025
Ex-Dividend Date	Mar 28, 2025

Share Statistics

Current Share Class	3.36B
Shares Outstanding	n/a
Shares Change (YoY)	-0.61%
Shares Change (QoQ)	-0.20%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	3.18B

Valuation Ratios

The trailing PE ratio is 18.73 and the forward PE ratio is 16.54.

PE Ratio	18.73
Forward PE	16.54
PS Ratio	6.46
PB Ratio	14.14
P/TBV Ratio	67.18
P/FCF Ratio	24.76
P/OCF Ratio	14.93
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.99, with an EV/FCF ratio of 25.73.

EV / Earnings	19.46
EV / Sales	6.72
EV / EBITDA	12.99
EV / EBIT	13.87
EV / FCF	25.73

Financial Position

The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.86.

Current Ratio	0.74
Quick Ratio	0.54
Debt / Equity	0.86
Debt / EBITDA	0.76
Debt / FCF	1.50
Interest Coverage	41.95

Financial Efficiency

Return on equity (ROE) is 88.12% and return on invested capital (ROIC) is 47.91%.

Return on Equity (ROE)	88.12%
Return on Assets (ROA)	23.29%
Return on Invested Capital (ROIC)	47.91%
Return on Capital Employed (ROCE)	58.02%
Revenue Per Employee	524,983
Profits Per Employee	181,173
Employee Count	77,349
Asset Turnover	0.77
Inventory Turnover	1.22

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -50.70% in the last 52 weeks. The beta is 0.21, so Novo Nordisk's price volatility has been lower than the market average.

Beta (5Y)	0.21
52-Week Price Change	-50.70%
50-Day Moving Average	64.89
200-Day Moving Average	92.65
Relative Strength Index (RSI)	46.68
Average Volume (20 Days)	302,686

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Novo Nordisk had revenue of EUR 40.64 billion and earned 14.02 billion in profits. Earnings per share was 3.15.

Revenue	40.64B
Gross Profit	34.40B
Operating Income	19.68B
Pretax Income	17.74B
Net Income	14.02B
EBITDA	20.82B
EBIT	19.68B
Earnings Per Share (EPS)	3.15

Full Income Statement

Balance Sheet

The company has 5.57 billion in cash and 15.92 billion in debt, giving a net cash position of -10.35 billion.

Cash & Cash Equivalents	5.57B
Total Debt	15.92B
Net Cash	-10.35B
Net Cash Per Share	n/a
Equity (Book Value)	18.57B
Book Value Per Share	4.18
Working Capital	-8.27B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 17.59 billion and capital expenditures -6.99 billion, giving a free cash flow of 10.61 billion.

Operating Cash Flow	17.59B
Capital Expenditures	-6.99B
Free Cash Flow	10.61B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 84.65%, with operating and profit margins of 48.43% and 34.51%.

Gross Margin	84.65%
Operating Margin	48.43%
Pretax Margin	43.65%
Profit Margin	34.51%
EBITDA Margin	51.23%
EBIT Margin	48.43%
FCF Margin	26.10%

Dividends & Yields

This stock pays an annual dividend of 1.53, which amounts to a dividend yield of 2.61%.

Dividend Per Share	1.53
Dividend Yield	2.61%
Dividend Growth (YoY)	21.20%
Years of Dividend Growth	5
Payout Ratio	48.61%
Buyback Yield	0.61%
Shareholder Yield	3.21%
Earnings Yield	5.34%
FCF Yield	4.04%

Dividend Details

Stock Splits

The last stock split was on September 13, 2023. It was a forward split with a ratio of 2.

Last Split Date	Sep 13, 2023
Split Type	Forward
Split Ratio	2

Scores

Novo Nordisk has an Altman Z-Score of 7.88.

Altman Z-Score	7.88
Piotroski F-Score	n/a